Agios Pharmaceuticals (AGIO) Gross Profit (2017 - 2026)

Agios Pharmaceuticals' Gross Profit history runs 9 years deep, the most recent figure standing at $19.4 million for Q1 2026.

• Quarterly Gross Profit rose 154.25% year-over-year to $19.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $59.5 million (up 83.48% YoY) and the FY2025 annual result came in at $47.7 million, up 47.47% from the prior year.
• Gross Profit was $19.4 million for Q1 2026 at Agios Pharmaceuticals, up from $18.1 million in the prior quarter.
• Across five years, Gross Profit topped out at $19.4 million in Q1 2026 and bottomed at $493000.0 in Q1 2022.
• A 5-year average of $8.0 million and a median of $7.1 million in 2024 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit jumped 925.35% — and 2025, when it gained 1.04%.
• Agios Pharmaceuticals' Gross Profit stood at $3.9 million in 2022, then surged by 67.23% to $6.5 million in 2023, then jumped by 45.31% to $9.5 million in 2024, then surged by 91.0% to $18.1 million in 2025, then gained by 7.4% to $19.4 million in 2026.
• Business Quant data shows AGIO's Gross Profit at $19.4 million in Q1 2026, $18.1 million in Q4 2025, and $11.2 million in Q3 2025.